Aclaris MK2 bears fruit

Aclaris’s refocus following the failure of its Jak inhibitors in alopecia is starting to pay off. The company opened up 140% this morning on promising phase II data with its oral rheumatoid arthritis project ATI-450, albeit in just 17 subjects.